Valuation: Positron Corporation

Market Cap 5.4Cr 4.82Cr 4.45Cr 4.04Cr 7.58Cr 511.49Cr 7.7Cr 54Cr 21Cr 267.98Cr 20Cr 20Cr 848.94Cr P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 5.29Cr 4.72Cr 4.35Cr 3.95Cr 7.42Cr 500.73Cr 7.53Cr 52Cr 21Cr 262.34Cr 20Cr 19Cr 831.07Cr EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
45.36%
Yield 2024 *
-
Yield 2025 -
1 day+3.41%
1 week+4.94%
Current month-4.93%
1 month-8.85%
3 months+2.60%
6 months-10.05%
Current year+1.80%
1 week 1.55
Extreme 1.55
1.75
1 month 1.43
Extreme 1.43
2
Current year 1.43
Extreme 1.43
2.74
1 year 1.27
Extreme 1.27
2.74
3 years 0.87
Extreme 0.87
2.94
5 years 0.07
Extreme 0.0682
2.94
10 years 0
Extreme 0
2.94
Manager TitleAgeSince
President 53 27/02/2018
Sales & Marketing - 24/06/2022
Corporate Officer/Principal 40 25/05/2018
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+3.41%+4.94%+13.33%+25.93% 5.4Cr
-2.44%-2.75%+19.42%+46.67% 26TCr
-1.92%-0.65%+5.46%+12.72% 16TCr
+3.07%+3.02%-16.37%+61.70% 15TCr
+2.73%+3.74%-55.91%-8.66% 6.45TCr
+0.12%+2.23%-15.36%-11.09% 5.21TCr
+0.42%+2.88%+11.08%+65.05% 5.19TCr
+0.74%+1.16%+15.98%+29.07% 5.1TCr
-2.56%-1.23%+18.87%+58.58% 5.01TCr
-1.18%+2.12%+30.09%+77.42% 4.49TCr
Average +0.24%+3.70%+2.66%+35.74% 8.87TCr
Weighted average by Cap. -0.47%+3.50%+3.03%+37.82%

Financials

2024 2025
Net sales 6L 5L 5L 4L 8L 5.57Cr 8L 58.28L 22.96L 2.92Cr 22.05L 21.58L 9.24Cr 5L 4L 4L 3L 6L 4.37Cr 7L 45.78L 18.03L 2.29Cr 17.32L 16.95L 7.25Cr
Net income -23.79L -21.24L -19.59L -17.8L -33.39L -23Cr -33.9L -2.36Cr -92.97L -12Cr -89.3L -87.39L -37Cr -1.06Cr -94.65L -87.32L -79.33L -1.49Cr -100.44Cr -1.51Cr -11Cr -4.14Cr -53Cr -3.98Cr -3.89Cr -166.7Cr
Net Debt 14.24L 12.71L 11.73L 10.66L 19.99L 13Cr 20.3L 1.41Cr 55.66L 7.07Cr 53.47L 52.32L 22Cr -11.36L -10.14L -9L -9L -15.95L -11Cr -16.19L -1.13Cr -44.4L -5.64Cr -42.65L -41.73L -18Cr
Projected Income Statement - Annual - Positron Corporation
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
10
Date Price Change Volume
22/26/22 $1.700 +3.41% 5,279
21/26/21 $1.644 -4.57% 819
20/26/20 $1.723 +1.34% 13,869
19/26/19 $1.700 +9.68% 13,445
16/26/16 $1.550 -4.32% 10,011
  1. Stock Market
  2. Stocks
  3. POSC Stock